DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Rilonacept

Rilonacept

  • Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES

    Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES

  • Targeted Review List Kaiser HMO, Multi-Choice, PPO, Senior Advantage Effective 1/01/2020

    Targeted Review List Kaiser HMO, Multi-Choice, PPO, Senior Advantage Effective 1/01/2020

  • Challenges and Approaches for the Development of Safer Immunomodulatory Biologics

    Challenges and Approaches for the Development of Safer Immunomodulatory Biologics

  • WHO EML Application Tocilizumab

    WHO EML Application Tocilizumab

  • Specialty Guideline Management

    Specialty Guideline Management

  • Prior Authorization Policy

    Prior Authorization Policy

  • Arcalyst® (Rilonacept)

    Arcalyst® (Rilonacept)

  • Section B Changed Classes/Guidelines Final

    Section B Changed Classes/Guidelines Final

  • Ep 3178848 A1

    Ep 3178848 A1

  • Quartz Medicare Advantage 2021 Part B Prior Authorization Criteria

    Quartz Medicare Advantage 2021 Part B Prior Authorization Criteria

  • Soluble Ligands As Drug Targets

    Soluble Ligands As Drug Targets

  • Arcalyst® (Rilonacept)/Ilaris® (Canakinumab)

    Arcalyst® (Rilonacept)/Ilaris® (Canakinumab)

  • A Arcalys T (Rilona Acept)

    A Arcalys T (Rilona Acept)

  • Therapeutic Class Overview Immunomodulators

    Therapeutic Class Overview Immunomodulators

  • NH Systemic Immunomodulator Criteria

    NH Systemic Immunomodulator Criteria

  • Rilonacept in the Management of Cryopyrin- Associated Periodic Syndromes (CAPS)

    Rilonacept in the Management of Cryopyrin- Associated Periodic Syndromes (CAPS)

  • Prior Authorization Criteria Non-TNF Biologic Therapies All Requests For

    Prior Authorization Criteria Non-TNF Biologic Therapies All Requests For

  • INN Working Document 05.179 Update 2011

    INN Working Document 05.179 Update 2011

Top View
  • Injections: Drugs NR Policy
  • Research in Your Backyard Developing Cures, Creating Jobs
  • CDER List of Licensed Biological Products With
  • (INN) for Biological and Biotechnological Substances
  • COVID19 As Immunology Boot Camp: Anti-Viral Defense, Cytokine Biology & Prospects for Therapy
  • Arcalyst® (Rilonacept)
  • Annual Report 2
  • International Nonproprietary Names (INN) for Biological and Biotechnological Substances
  • EMEA Annual Report 2007 EMEA/MB/17464/2008 2.4, CURRENT Page 2/138 6
  • FDA Approval of ARCALYST® (Rilonacept) for Recurrent Pericarditis
  • Who Drug Information
  • Arcalyst (Rilonacept)
  • C9050 Injection, Emapalumab-Lzsg, 1 Mg C9122
  • Changes Highlighted Final Version Date of Issue
  • ATC-Index Mit DDD-Angaben Für Den Deutschen Arzneimittelmarkt Berlin 2013, 12
  • Pharmaabkommen A1 E
  • (12) United States Patent (10) Patent No.: US 9.295,731 B2 Nguyen (45) Date of Patent: Mar
  • ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019


© 2024 Docslib.org    Feedback